Santra 1 mg

Santra is an aromatase inhibitor which is used for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer and treatment of advanced breast cancer in postmenopausal women with disease progression following Tamoxifen therapy.

Due to the fact that Santra act as anti-estrogens, this medication is used offlabel by male bodybuilders as part of their Post Cycle Therapy (PCT) to restore the natural level of testosterone in the body, so that they can avoid the undesirable effects of estrogen such as gynecomastia that can become apparent at the end of a steroid cycle.

The active ingredient present in Santra is Anastrozole. Each Santra tablet contains 1 mg of Anastrozole.

Santra is used in women who have finished menopause for treatment of early breast cancer. It is used in the following areas: after surgery, with or without radiation, in women whose breast cancer is hormone receptor-positive, first treatment of locally advanced or metastatic breast cancer in women whose breast cancer is hormone receptor-positive or the hormone receptors are not known, treatment of advanced breast cancer, if the cancer has grown, or the disease has spread after Tamoxifen therapy. The recommended dosage of Santra is 1 mg tablet taken once daily.

Take Santra exactly as prescribed by your doctor. Keep taking Santra for as long as your doctor prescribes it for you. Take one tablet each day with or without food. If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose. Take your next regularly scheduled dose. Do not take two doses at the same time.

If you have taken more Santra than your doctor has prescribed, contact your doctor right away. Do not take any additional Santra tablet until instructed to do so by your doctor.

Talk with your doctor about any health changes you have while taking Santra.

During clinical trials dosages up to 60 mg in a single dose given to healthy male volunteers and up to 10 mg daily given to postmenopausal women with advanced breast cancer; these dosages were tolerated.

There is no specific antidote to Santra overdosage and the treatment must be symptomatic. In the management of an overdose, consider that multiple agents may have been taken. Vomiting can be induced if the patient is alert. Dialysis may be helpful because Santra is not highly protein bound.